What type of study is this?

This is a Literature Review study.

December 8, 2025BloodOpen Access

The use of eculizumab and tocilizumab in the treatment of hyperhemolysis syndrome, a literature review

View Full Paper

Ask AI

Bookmark

Authors

AAAli Aqel MYMohamed A. Yassin

Discussion

Member takes

Implication

Literature review shows eculizumab and tocilizumab improve anemia in hyperhemolysis syndrome, indicating their potential benefits for hemoglobinopathies.

Key Points

Eculizumab and tocilizumab improved anemia in 18 of 22 hyperhemolysis syndrome cases treated, demonstrating their efficacy.
Among 22 patients, the average age was 29.5 years, with hemoglobinopathies like sickle cell disease predominating the cohort.
Observational analysis of 22 reported cases through various research databases highlighted significant improvements with treatment and raised the need for more studies.
The rarity of hyperhemolysis syndrome and its complexities underscore the challenges in understanding its pathology and treatment options.

Cite This Study

Aqel et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e266 https://doi.org/10.1182/blood-2025-6508

View Full Paper

Ask AI

Bookmark

Implication

Literature review shows eculizumab and tocilizumab improve anemia in hyperhemolysis syndrome, indicating their potential benefits for hemoglobinopathies.

The use of eculizumab and tocilizumab in the treatment of hyperhemolysis syndrome, a literature review

Discussion

Member takes

Implication

Key Points

Cite This Study

The use of eculizumab and tocilizumab in the treatment of hyperhemolysis syndrome, a literature review

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider